Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy

Systemic administration of immune checkpoint blockade (ICB) monoclonal antibodies (mAbs) can unleash antitumor functions of T cells but is associated with variable response rates and off-target toxicities. We hypothesized that antitumor efficacy of ICB is limited by the minimal accumulation of mAb w...

Descripción completa

Detalles Bibliográficos
Autores principales: Francis, David M., Manspeaker, Margaret P., Schudel, Alex, Sestito, Lauren F., O’Melia, Meghan J., Kissick, Haydn T., Pollack, Brian P., Waller, Edmund K., Thomas, Susan N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377700/
https://www.ncbi.nlm.nih.gov/pubmed/32998971
http://dx.doi.org/10.1126/scitranslmed.aay3575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377700/
https://www.ncbi.nlm.nih.gov/pubmed/32998971
http://dx.doi.org/10.1126/scitranslmed.aay3575

Ejemplares similares